| Identification | Back Directory | [Name]
PYR-GLN-PHE-N-ME-PHE-SAR-LEU-MET-NH2 | [CAS]
77128-69-9 | [Synonyms]
DiMe-C7
[pGlu5,MePhe8,Sar9]substance P(5-11)
PYR-GLN-PHE-N-ME-PHE-SAR-LEU-MET-NH2
GLP-GLN-PHE-(NME)PHE-SAR-LEU-MET-NH2
[GLP5,(ME)PHE8,SAR9] SUBSTANCE P (5-11)
(PYR5,N-ME-PHE8,SAR9)-SUBSTANCE P (5-11)
PGLU-GLN-PHE-N-METHYL-PHE-SAR-LEU-MET-NH2
PGLU5,MEPHE8,SAR9-SUBSTANCE P FRAGMENT*5 -11
substance P (5-11), pGlu(5)-MePhe(8)-MeGly(9)-
SUBSTANCE P (PGLU5,MEPHE8,SAR9)-*FRAGMEN T 5-11
Substance P, fragment 5-11, [pGlu5, MePhe8, Sar9]
[pglu5, n-me-phe8, sar9]-substance p fragment 5-11
SUBSTANCE P [PGLU5, N-ME-PHE8, SAR9]-FRAGMENT 5-11
pGlu-L-Glu(NH2)-L-Phe-N-Methyl-L-Phe-Sar-L-Leu-L-Met-NH2
5-Oxo-L-Pro-L-Gln-L-Phe-N-methyl-L-Phe-N-methyl-Gly-L-Leu-L-Met-NH2
(Pyr 5,N-Me-Phe8, Sar 9)-Substance P (5-11) Pyr-Gln-Phe-N-Me-Phe-Sar-Leu-Met-NH2
L-Methioninamide, 5-oxo-L-prolyl-L-glutaminyl-L-phenylalanyl-N-methyl-L-phenylalanyl-N-methylglycyl-L-leucyl- (9CI) | [Molecular Formula]
C43H61N9O9S | [MDL Number]
MFCD00133835 | [MOL File]
77128-69-9.mol | [Molecular Weight]
880.06 |
| Chemical Properties | Back Directory | [Boiling point ]
1291.2±65.0 °C(Predicted) | [density ]
1.257±0.06 g/cm3(Predicted) | [storage temp. ]
−20°C | [form ]
Solid | [pka]
13.13±0.20(Predicted) | [color ]
White to off-white | [Sequence]
pGlu-Gln-Phe-N-Methyl-Phe-Sar-Leu-Met-NH2 |
| Hazard Information | Back Directory | [Uses]
[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is a Substance P (HY-P0201) analogue that has approximately the same effects as Substance P (HY-P0201) on neurokinin 1 receptor (NK1R) in rat brain, but with a much longer duration of action. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) selectively activates dopamine metabolism in the mesencephalon and midbrain cortex of the rat brain. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) also increases motor activity and induces recovery of addictive agent-seeking behavior in rats[1][2][3]. | [in vivo]
[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (2 μg/side; inject into the ventral tegmental area; single) exhibits selective activation of mesolimbic and mesocortical dopamine metabolism in rat brain[1].
[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (0.5, 1.5, 3 μg/side; inject into the ventral tegmental area; single) increases motor activity and induces recovery of addictive agent-seeking behavior in rats[2]. | Animal Model: | Male Sprague-Dawley rats (300-350 g)[1]. | | Dosage: | 2 μg/side | | Administration: | Inject into the ventral tegmental area; single | | Result: | Selectively activated mesolimbic and mesocortical dopamine metabolism. |
| Animal Model: | Male Wistar rats (300-350 g)[2]. | | Dosage: | 0.5, 1.5, 3 μg/side | | Administration: | Inject into the ventral tegmental area; single | | Result: | Significantly increased locomotor activity when at 3 μg/side. |
| [References]
[1] Elliott PJ, et al. Selective activation of mesolimbic and mesocortical dopamine metabolism in rat brain by infusion of a stable substance P analogue into the ventral tegmental area. Brain Res. 1986 Jan 15;363(1):145-7. DOI:10.1016/0006-8993(86)90667-0
[2] Eison AS, et al. Substance P analog, DiMe-C7: evidence for stability in rat brain and prolonged central actions. Science. 1982 Jan 8;215(4529):188-90. DOI:10.1126/science.6171884
[3] Placenza FM, et al. Infusion of the substance P analogue, DiMe-C7, into the ventral tegmental area induces reinstatement of cocaine-seeking behaviour in rats. Psychopharmacology (Berl). 2004 Dec;177(1-2):111-20. DOI:10.1007/s00213-004-1912-9 |
|
|